Endotoxin Attacks the Cardiovascular System: Black Death at the Tollgate

Journal of the American College of Cardiology

Volumn 42, Issue 9, 2003, Pages 1663-1665

  Lew, Wilbur Y W ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; CARDIOVASCULAR SYSTEM; DISEASE SEVERITY; EDITORIAL; ENDOTOXEMIA; HUMAN; IMMUNE RESPONSE; MORTALITY; MULTIPLE ORGAN FAILURE; OXIDATIVE STRESS; PRIORITY JOURNAL; SEPSIS; SHOCK; SURVIVAL; VASOCONSTRICTION; VASODILATATION;

EID: 0242551919     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.08.006     Document Type: Editorial

References (20)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
3. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-91.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
5. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003;3:169-76.
6. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001;7:167-202.
7. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003;2:391-405.
8. 2+ in cardiac myocytes. Circ Res 1997;81:1011-20.
9. 1 receptors. Am J Physiol Heart Circ Physiol 2002;283:H461-7.
10. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002;166:1197-205.
11. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-24.
12. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor-4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-92.
13. Pleiner J, Mittermayer F, Schaller G, Marsik C, MacAllister RJ, Wolzt M. Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol 2003;42:1656-62.
14. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
15. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
16. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42.
17. Rothenburger M, Soeparwata R, Deng MC, et al. The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. J Am Coll Cardiol 2001;38:124-30.
18. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999;34:1975-81.
19. Macdonald J, Galley HF, Webster NR. Oxidative stress and gene expression in sepsis. Br J Anaesth 2003;90:221-32.
20. Grover R, Lopez A, Lorente J, et al. Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock (abstr). Crit Care Med 1999;27:A33.